ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Read more
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases Read more
Termination of Bridge Biotherapeutics’s Collaboration and License Agreement with Boehringer Ingelheim Read more
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2 Read more